Tentative Program

30th Euro Global Summit and Expo on Vaccines & Vaccination
June 14-16, 2018 | Barcelona, Spain

***For available speaker slots***
eurovaccines@vaccineconference.com
# Program at a Glance

## Day 1

<table>
<thead>
<tr>
<th>Time</th>
<th>General Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00-09.00</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 1</th>
<th>Session 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00-09.15</td>
<td>Inaugural Address</td>
<td></td>
</tr>
<tr>
<td>09.15-09.45</td>
<td>Keynote/Plenary Talk 1</td>
<td>Keynote/Plenary Talk 2</td>
</tr>
<tr>
<td>09.45-10.15</td>
<td>Keynote/Plenary Talk 2</td>
<td>Keynote/Plenary Talk 3</td>
</tr>
<tr>
<td>10.15-10.45</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Panel Discussions/Group Photo

Coffee/Tea Break 10.45-11.00 (Networking)

11.00-12.40 5 Speakers (20 Mins Each)

Lunch Break 12.40-13.30

13.30-15.30 6 Speakers (20 Mins Each)

Coffee/Tea Break 15.30-15.45 (Networking)

15.45-17.25 5 Speakers (20 Mins Each)

## Day 2

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 1</th>
<th>Session 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00-10.40</td>
<td>5 Speakers (20 Mins Each)</td>
<td>5 Speakers (20 Mins Each)</td>
</tr>
</tbody>
</table>

Coffee/Tea Break 10.40-10.55 (Networking)

10.55-12.35 5 Speakers (20 Mins Each) 5 Speakers (20 Mins Each)

Lunch Break 12.35-13.25

13.25-15.05 5 Speakers (20 Mins Each) 5 Speakers (20 Mins Each)

Coffee/Tea Break 15.05-15.20 (Networking)

15.20-17.00 5 Speakers (20 Mins Each) 5 Speakers (20 Mins Each)

## Day 3

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 1</th>
<th>Session 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00-10.40</td>
<td>5 Speakers (20 Mins Each)</td>
<td>5 Speakers (20 Mins Each)</td>
</tr>
</tbody>
</table>

Coffee/Tea Break 10.40-10.55 (Networking)

10.55-12.35 5 Speakers (20 Mins Each) 5 Speakers (20 Mins Each)

Lunch Break 12.35-13.25

13.25-15.05 5 Speakers (20 Mins Each) 5 Speakers (20 Mins Each)

## Awards & Closing Ceremony

NOTE: Program Schedule is subject to change with final allotment of the speaker slots

For more Details PS: http://europe.vaccineconferences.com/
eurovaccines@vaccineconference.com | eurovaccines@conferenceseries.net
Conference Highlights

- Human Vaccines - Infectious & Non Infectious Diseases
- Vaccine Research & Development
- HIV Vaccines
- Cancer Vaccines
- Childhood Vaccines
- Vaccine Safety & Efficacy
- Vaccination for pregnant women
- Vaccine Adjuvants & Delivery Technologies
- Veterinary vaccines
- Geriatric Immunization
- Vaccines against Viral & Bacterial Diseases
- Human Preventive & Therapeutic Vaccines
- Hepatitis Vaccines
- DNA Vaccines
- Mucosal Vaccines
- Plant-based Vaccines
- HPV Vaccines
- Travel Immunization
- Vaccines against Vector-borne Diseases
- Tuberculosis Vaccines

For detailed sessions, please visit: http://europe.vaccineconferences.com/call-for-abstracts.php
Submit your abstract online at: http://europe.vaccineconferences.com/abstract-submission.php
Register online: http://europe.vaccineconferences.com/registration.php
Glimpses of Past Conferences
Glimpses of Euro Vaccines 2017
Plan your Trip to Barcelona, Spain

La Sagrada Familia

Magic Fountain show

Park Guell by Gaudi

FC Barcelona museum & Camp Nou stadium

Cathedral Santa Creu

Modernist buildings
### Keynote Forum

**Introduction**

**Title:** DNA immunization to prime the high quality antigen-specific B cell responses – a powerful pathway to induce protective antibodies  
**Shan Lu,** University of Massachusetts Medical School, USA

**Title:** Pan-Lassa fever vaccine for prevention and post-challenge applications  
**Igor S Lukashevich,** University of Louisville, USA

### Group Photo

**Title:** Altered vaccine immune responses to different Toll-Like receptor activators  
**Kei Amemiya,** US Army Medical Research Institute of Infectious Diseases, USA

### Networking & Refreshments Break

**Title:** Addressing challenges and solution for using T cell based assays for immune monitoring  
**Magdalena Tary-Lehmann,** Cellular Technology Limited, USA

**Title:** Plant virus nanoparticles: New applications for developing countries  
**Kathleen Hefferon,** Cornell University, USA

**Title:** Stability modeling to predict vaccine shelf-life and evaluate impact of temperature excursions from the “cold chain”  
**Didier Clenet,** Sanofi-Pasteur, France

### Lunch Break

**Title:** Multi-epitope fusion antigen (MEFA), novel technology for structural vaccinology  
**Weiping Zhang,** Kansas State University, USA

**Title:** Singapore Immunology Network’s clinical immunomonitoring platform for the assessment of immune responses in cohort studies and clinical trials  
**Brian Abel,** A*STAR, Singapore

**Title:** Mucosal vaccination with accessory antigens provides surprisingly robust protection against early SIV replication: Underappreciated role of location and immunodominance in vaccination against chronic infection  
**Peter Johannes Holst,** University of Copenhagen, Denmark

### Network & Refreshment Break

**Title:** Polio outbreak stopped in the Middle East, efforts are still needed  
**Randa Hamadeh,** Ministry of Public Health, Lebanon

### Young Researchers Forum

**Title:** Modified MHCII associated invariant chain induces increased antibody responses against Plasmodium falciparum antigens after adenoviral vaccination  
**Cyrielle Fougeroux,** Copenhagen University, Denmark

**Title:** Oil-based adjuvants and intradermal vaccine delivery: Th1 vs. Th2 response  
**Zrinka Oreskovic,** Veterinary Research Institute, Czech Republic
Title: Bovine herpesvirus type 4-BAC as an attractive viral vector for vaccination and gene therapy
Touraj Aligholipour Farzani, Ankara University, Turkey

Panel Discussion

Day 2 | June 20, 2017 | Tuesday
Sunset 2

Keynote Forum

Title: Live, attenuated vaccines in animal health: VitamFero’s products and a few others
Pascal Breton, VitamFero, France

Title: Pneumococcal polysaccharide vaccines for elderly: Here, there and everywhere
Ger T Rijkers, University College Roosevelt, Netherlands

Panel Discussion

Network & Refreshment Break

Sessions: Immunization for Older Adults | Cancer Vaccines | Vaccines against Vector-borne Diseases | Human Preventive & Therapeutic Vaccines
Session Chair: Ger T Rijkers, University College Roosevelt, Netherlands

Session Introduction

Title: Exploiting defects of type I interferon response in tumor cells for oncolytic immunotherapy with attenuated measles virus
Jean-François Fonteneau, University of Nantes, France

Title: Sequential administration of a MVA-based MUC1 cancer vaccine and the TLR9 ligand Litenimod (Li28) improves local immune defense against tumors
Karola Rittner, Transgene SA, France

Title: Biogenic selenium nanoparticles can shift the immune response of breast cancer bearing mice toward Th1 pattern
Mohammad Hosssein Yazdi, Tehran University of Medical Sciences, Iran

Title: Recombinant lapidated subunit vaccines induce robust immunity against all four serotypes of dengue virus
Hsin-Wei Chen, National Health Research Institutes, Taiwan

Lunch Break

Title: Therapeutic vaccination in chronic infectious diseases: The place of vectored vaccines
Geneviève Inchauspé, Transgene SA, France

Sessions: Veterinary vaccines | Vaccine Research & Development | Vaccine Adjuvants & Delivery Technologies | HIV Vaccines
Session Chair: Pascal Breton, VitamFero, France

Session Introduction

Title: A toll-like receptor 2 agonist-fused antigen enhanced antitumor immunity by increasing antigen presentation and the CD8 memory T cells population
Chih-Hsiang Leng, National Health Research Institutes, Taiwan

Title: Development of innovative vaccines by the combination of novel technologies
Fumihiko Takeshita, Daiichi Sankyo Co. Ltd., Japan

Title: Degradable emulsion as vaccine adjuvant reshapes antigen-specific immunity and ameliorates vaccine efficacy
Ming-Hsi Huang, National Health Research Institutes, Taiwan

Title: Kinetics of myeloid derived suppressor cells (MDSC) and their effect on vaccine-specific responses during the first year of life
Ana Gervassi, Center for Infectious Disease Research, USA

Network & Refreshment Break

Panel Discussion

Poster Presentations

EVACC 01
Title: Development of a peptide vaccine platform for brain tumor immunotherapy that incorporates adjuvant CD27 stimulation for enhanced T cell immunity
Katherine Riccione, Duke University, USA

Title: Clostridium difficile flagellin FlIC as an adjuvant to induce a protective gut mucosal immune response
Jean-François Bruxelle, University of Paris-Su, France
EVACC 03
Title: LPS/Endotoxins molecular diversity impacting vaccines and adjuvants activities and toxicity
Alexey Novokiv, LPS-Biosciences, France

EVACC 04
Title: Construction for minimal positive conditions for the safety of brain from vaccines to be supplied quickly at widespread epidemics
Sun Shin Yi, Soonchunhyang University, Republic of Korea

EVACC 05
Title: Development and preclinical evaluation of 15 pneumococcal polysaccharide CRM197 conjugate candidate vaccines in mouse model
Huyen T Pham, Konkuk University, South Korea

EVACC 06
Title: Study for establishment of 1st National Reference Standard for cell-derived Japanese encephalitis vaccine (Beijing strain)
Ji Young Hong, National Institute of Food and Drug Safety Evaluation, South Korea

EVACC 07
Title: Flavivirus nonstructural protein 1-based recombinant vaccines
Ching-Len Liao, National Health Research Institutes, Taiwan

EVACC 08
Title: Heterologous prime-boost tetravalent dengue vaccine strategy elicits complete protection against DENV-2 in non-human primates
Chutitorn Ketloy, Chulalongkorn University, Thailand

Awards for Poster Presentations
Day 3 | June 21, 2017 | Wednesday
Extended Networking & Lunch

Bookmark your dates
30th Euro Global Summit and Expo on
Vaccines & Vaccination
Jun 21-23, 2018  Barcelona, Spain

E: eurovaccines@conferenceseries.net; eurovaccines@vaccineconference.com
W: vaccines.global-summit.com/europe
Registrations

Appia

Opening Ceremony

Keynote Forum

Introduction

Title: Development of the full length single chain gp120-CD4 (FLSC), a novel vaccine for HIV prevention
Timothy R Fouts, Profectus Biosciences Inc., USA

Title: Vaccines moving beyond the next frontier
Rene Labatut, Sanofi Pasteur, France

Networking & Refreshments Break

Track 1: Cancer Vaccines
Track 2: Vaccine Products and Delivery Technologies
Track 3: Vaccine Research and Development
Track 4: Vaccines for Respiratory Infections
Track 5: HIV Vaccines
Track 6: Veterinary vaccines
Session Chair: Timothy R Fouts, Profectus Biosciences Inc., USA
Session Co-chair: Qingsheng Li, University of Nebraska-Lincoln, USA

Title: Pre-clinical evaluation of the therapeutic application of a vaccine targeting the 12 protease cleavage sites
Ma Luo, University of Manitoba, Canada

Title: Distinct transcriptome profiles of Gag-specific CD8+ T cells temporally correlated with the protection elicited by live attenuated SIV
Qingsheng Li, University of Nebraska-Lincoln, USA

Title: TAT, the forgotten target that could help to cure from HIV
Erwann P Loret, ETRAV Laboratory, France

Title: Community engagement during the Ebola vaccine trial in Guinea
Godwin Enwere, World Health Organization, Switzerland

Title: Pre-clinical toxicology considerations in vaccine
Nabil Al-Humadi, Food and Drug Administration, USA

Lunch Break

Title: Codon harmonization, a step beyond optimization to capture the natural rhythm of protein translation
Bettina Werle, Bioaster, France

Title: Development of lipid based oral vaccine formulations
Sarah Margaret Hook, University of Otago, New Zealand

Title: Viral vectored genetic vaccines: Current status and future perspectives
Antonella Folgori, Reithera SRL, Italy

Title: Active immunization against proprotein convertase subtilisin/kexin type 9 (PCSK9): A new strategy to control hyperlipidemia
Gunther Staffler, AFFiRiS AG, Austria

Title: Development of a production and purification platform for virus like particles (VLP) vaccine candidates: A case study
Anissa Boumlic-Courtade, Merck Life Science, France

Title: MATS: Global coverage estimates for 4CMenB, a novel multi-component meningococcal B vaccine
Duccio Medini, GSK Vaccines, Italy

Networking & Refreshments Break

Title: Implementing a randomized control trial (RCT) in the context of an Ebola epidemic
Godwin Enwere, World Health Organization, Switzerland

Title: Vaccination with self-adjuvanted protein nanoparticles provides protection against lethal influenza challenge
Peter Burkhard, Alpha-O Peptides AG, Switzerland

Title: Plant expression platforms for vaccine production
Kathleen Hefferon, Cornell University, USA
<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>What do Lebanese women know about cervical cancer and human papillomavirus prevention? A report on awareness levels in urban communities</td>
<td>Jacques Choucair, Saint Joseph University, Lebanon</td>
<td></td>
</tr>
<tr>
<td>Young Researchers Forum</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isolation and characteristics identification of bovine rotaviruses from vaccinated dairy calves in Morocco</td>
<td>Ennima Imane, University Mohammed V of Rabat, Morocco</td>
<td>Morocco</td>
</tr>
<tr>
<td>Bluetongue virus (BTV) serological survey and evidence of emergent BTV-8 serotype in Morocco</td>
<td>Kamar Drif, Institut Agronomique et Veterinaire Hassan II, Morocco</td>
<td>Morocco</td>
</tr>
<tr>
<td>Evaluation of the protection conferred by an attenuated vaccine (Mass-type H120) of avian infectious bronchitis against a new emerging Italy 02 genotype in Moroccan broiler chickens</td>
<td>Khadija Khataby, University Hassan II of Casablanca, Morocco</td>
<td>Morocco</td>
</tr>
<tr>
<td>Panel Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 2 June 17, 2016</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Appia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Towards affordable conjugate vaccines: Efficient chemistry and low cost carrier protein</td>
<td>Andrew Lees, Fina Biosolutions LLC, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Human vaccines and vaccination for non-infectious diseases</td>
<td>Giulio Filippo Tarro, Foundation T. &amp; L. de Beaumont Bonelli for Cancer Research, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>Networking &amp; Refreshments Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Challenges and dilemmas about vaccines against the herpesviruses : The case of EBV</td>
<td>Emmanuel Drouet, Université Grenoble-Alpes, France</td>
<td>France</td>
</tr>
<tr>
<td>Track 7: Vaccines against Infectious diseases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Track 8: Viral Vaccines</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Track 9: Bacterial Vaccines</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Track 10: Childhood Vaccines</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Track 11: Hepatitis Vaccines</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Track 12: Toxoid Vaccines</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Session Chairs: Giulio Filippo Tarro, Foundation T. &amp; L. de Beaumont Bonelli for Cancer Research, Italy</td>
<td>Andrew Lees, Fina Biosolutions LLC, USA</td>
<td></td>
</tr>
<tr>
<td>Lunch Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rapid development of an oral Zika virus vaccine</td>
<td>Sean N Tucker, Vaxart Inc., USA</td>
<td>USA</td>
</tr>
<tr>
<td>Preclinical development of HeV-sG as a vaccine and m102.4 as a post exposure prophylaxis against henipavirus infections</td>
<td>Timothy R Fouts, Profectus Bio-Sciences, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Measles: Need for continued vaccination and novel vaccines post virus eradication</td>
<td>S Louise Cosby, Agri-Food and Biosciences Institute, UK</td>
<td>UK</td>
</tr>
<tr>
<td>Evaluation of genetic stability of transgenes in vaccine</td>
<td>Ali Azizi, Sanofi Pasteur, Canada</td>
<td>Canada</td>
</tr>
<tr>
<td>Process development for pneumococcal protein vaccines based on recombinant pneumococcal surface protein A (PspA) and hybrids of PspA and pneumolysin toxoid</td>
<td>Viviane Maimoni Goncalves, Instituto Butantan, Brazil</td>
<td>Brazil</td>
</tr>
<tr>
<td>The key person influences flu vaccination among health workers: Perspective study of social network</td>
<td>Xiaoning Hao, China National Health Development Research Center, China</td>
<td>China</td>
</tr>
<tr>
<td>Pneumococcal conjugate vaccine: Use of pneumococcal surface protein A (PspA) as carrier</td>
<td>Giovana Cappio Barazzzone, Instituto Butantan, Brazil</td>
<td>Brazil</td>
</tr>
<tr>
<td>Construction and immunological study on recombinant multi-epitope adenovirus vaccine for influenza virus</td>
<td>Hui-jun Lu, Changchun Veterinary Institute of CAAS, China</td>
<td>China</td>
</tr>
<tr>
<td>Pneumococcal inactivated whole cell vaccine: Development of the production process</td>
<td>Viviane Maimoni Goncalves, Instituto Butantan, Brazil</td>
<td>Brazil</td>
</tr>
<tr>
<td>Knowledge, attitude and practices and influencing factors related to seasonal influenza vaccination among healthcare workers in Qingdao, China, 2013-14: A prospective cohort study</td>
<td>Xiaoning Hao, China National Health Development Research Center, China</td>
<td>China</td>
</tr>
<tr>
<td>Polio outbreak review in the Middle East and polio immunization mop-up campaigns in the Lebanese/Syrian refugees’ context and post campaign results</td>
<td>Randa Hamadeh, Ministry of Public Health, Lebanon</td>
<td>Lebanon</td>
</tr>
<tr>
<td>Networking &amp; Refreshments Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prevalence of tuberculin negativity after BCG vaccination in the under five Saudi children and the need for revaccination</td>
<td>Fahad Saleh Al-Tayyeb, King Abdulaziz Medical City, KSA</td>
<td>KSA</td>
</tr>
<tr>
<td>Vaccination of hepatitis B in healthy adults: Effect of sex and age, two protocols of revaccination in non-responders</td>
<td>Jacques Choucair, Saint Joseph University, Lebanon</td>
<td>Lebanon</td>
</tr>
<tr>
<td>Panel Discussion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Breakout
Cassia Meeting Room

Workshop on
Revisiting HIV inactivation, elite controllers, immunogenetics and HIV therapeutic vaccines

Session Chairs: Barbara Ensoli, National AIDS Center-Istituto Superiore di Sanità, Italy
Felipe Garcia Alcaide, Hospital Clinic de Barcelona, Spain

Title: Expanding the findings of RV144 to South Africa: P5 Initiative
Glenda Gray, South African Medical Research Council, South Africa
Title: Therapeutic vaccination with Tat restores immune homeostasis, promotes proviral DNA decay and induces cross-clade neutralizing antibodies in patients on HAART: Results from phase II clinical trials in Italy and South Africa
Barbara Ensoli, National AIDS Center-Istituto Superiore di Sanità, Italy

Networking & Refreshments
Break

Title: Current strategies for HIV remission: The role of therapeutic vaccines
Felipe Garcia Alcaide, Hospital Clinic de Barcelona, Spain
Title: Synthetic DNA vaccines for difficult mucosal viruses including HIV
Jean D. Boyer, Inovio Pharmaceuticals Inc., USA
Title: Potential development of inactivated HIV-1 transmitted/founder virus (T/F) vaccine
Adan Rios, PhotoImmune Biotechnology Inc., USA

11:50-12:20 Discussion
Lunch Break

Session Chairs: Marc H.V. Van Regenmortel, Biotechnology School of the University of Strasbourg, France
Eric Sandstrom, Karolinska Institutet, Sweden

Title: HIV vaccine development: Is a moral wrong occurring?
Mike King, University of Otago, New Zealand
Title: Reverse HIV vaccinology failed because it has no sound theoretical basis in the case of this virus
Marc H.V. Van Regenmortel, Biotechnology School of the University of Strasbourg, France
Title: HIV replication is suppressed by CD8+T regulatory cells in elite controllers
Jean Marie Andrieu, Paris-Descartes University, France
Title: Concerns in the planning of therapeutic immunizations in HIV infected patients aiming to harness HLA E restricted CD8+T-cell HIV suppressive activity
Eric Sandstrom, Karolinska Institutet, Sweden

Networking & Refreshments
Break

Title: Multiple immunogenetic aspects in susceptibility to HIV-1 infection progression toward AIDS and rational vaccine design
Massimo Amicosante, University of Rome, Italy

Workshop Discussion
Poster Presentations

EVACC 01 Role of insulin like growth factor-1 derived from macrophages in an influenza vaccine induced humoral immune response
Jae-Hwan Nam, Catholic University of Korea, South Korea
EVACC 02 Visualization of immune response to hepatitis B vaccination by in vivo small animal imaging
Hyewon Youn, Seoul National University, South Korea
EVACC 03 Development immunogen for protection against PRRSV infection using Korean isolates ORF5 protein expression using baculovirus expression system
Sun Shin Yi, Soonchunhyang University, South Korea
EVACC 04 Vaccine potentials of excretory-secretory antigens of 4 week old juveniles against Fasciola gigantica in mice
Narin Changklungmoa, Burapha University, Thailand
EVACC 05 Vaccine potentials of recombinant mature cathepsin L1H against Fasciola gigantica in mice
Pornanan Kueakhai, Burapha University, Thailand
EVACC 06 Characterization and vaccination of the cytosolic Fasciola gigantica superoxide dismutase
Wipaphorn Jaikua, Mahidol University, Thailand
EVACC 07 Study for manufacture and establishment of 1st national standard material for cell derived Japanese encephalitis vaccine (Beijing strain)
Ji Young Hong, National Institute of Food and Drug Safety Evaluation, Korea
EVACC 08 Histone deacetylase 10 (HDAC 10) deacetylates Foxp3 and modulates its stability
Suna Gu, Chonbuk National University, Republic of Korea
EVACC 09 In silico design of epitope based peptide vaccine against virulent strains of HN-Newcastle disease virus (NDV) in poultry species
Marwa Mohamed Osman, Africa City of Technology, Sudan

Day 3 June 18, 2016

Appia

Track 13: DNA Vaccines
Track 14: Vaccine Safety and Efficacy
Track 15: Vaccine Adjuvants
Track 16: Tuberculosis Vaccines
Track 17: Vaccination for Pregnant Women
Track 18: Human Preventive and Therapeutic Vaccines
Session Chair: Emmanuel Drouet, Université Grenoble-Alpes, France
Session Co-Chair: Sheikh Mohammad Fazle Akbar, Toshiba General Hospital, Japan

Session Introduction

Title: Vaccines for pregnant women - challenges and opportunities for harmonized safety monitoring
Sonali Kochhar, Global Healthcare Consulting, India

Title: Exploiting a high dose murine challenge model for HSV to identify potential DNA prime subunit boost vaccine strategies that could be translated to human clinical trials
Timothy R Fouts, Profectus Biosciences Inc., USA

Networking & Refreshments

Break

Title: Operational experience and lessons learned on influenza vaccination post authorization safety studies
Ombretta Palucci, Quintiles, Switzerland

Title: Post-marketing surveillance of BCG vaccination
Ruwen Jou, Tuberculosis Research Center at Centers for Disease Control, Taiwan

Title: Novel vaccine adjuvants for animal infectious diseases
Jishu Shi, Kansas State University, USA

Title: Emerging market challenges: Development of a thermostable and immunologically active solid HPV vaccine formulation
Ramesh Chintala, Merck & Co. Inc., USA

Lunch Break

Title: Immunogenicity of VLP forming baculoviral DNA vaccine
Young Bong Kim, Konkuk University, Republic of Korea

Title: Targeting TLR9 and TLR21 to develop vaccine adjuvant for different species
Tsung-Hsien Chuang, National Health Research Institutes, Taiwan

Title: Therapeutic vaccines for treatment of allergic and autoimmune diseases
Zhikang Peng, University of Manitoba, Canada

Title: Therapeutic vaccines against chronic hepatitis-B virus and related complications
Sheikh Mohammad Fazle Akbar, Toshiba General Hospital, Japan

Panel Discussion & Closing Ceremony
## Keynote Forum

**Introduction**

**Allan Cripps**  
Pro Vice Chancellor, Griffith University, Australia

**Nikolai Petrovsky**  
President, Global Vaccines conferences, OMICS International, Research Director, Vaxine, Australia

---

### Track 1: Technologies for The Design, Discovery, Formulation and Administration of Vaccines

Title: Rational vaccine design against complex pathogens in the OMICS era  
Denise Doolan, QIMR Berghofer, Australia

Title: Development of a Passive RSV Vaccine for Infants as an Alternative to Maternal Vaccination  
Filip Dubovsky, MedImmune/AstraZeneca, USA

Title: A dendritic cell-targetted vaccine loaded with a glyceraldehyde-3-phosphate dehydrogenase peptide confers wide protection to listeriosis in susceptible and resistant mice  
Carmen Alvarez-Dominguez, Proteomics and Vaccines, Spain

Title: Development and assessment of multivalent recombinant vaccines for bovine respiration disease  
Timothy J Mahony, The University of Queensland, Australia

---

### Track 2: Vaccines For Pregnant Women

**Helle Bielefeldt-Ohmann**, Australian Infectious Diseases Research Centre, Australia

Title: Advax-adjuvanted killed Japanese Encephalitis Virus (JEV) vaccine is safe in pregnant mares and in foals and induces robust immunological memory

Title: Achievements and challenges in post-exposure vaccine development  
Yuzhang Wu, The Third Military Medical University, China

**Zakaria Hmama**, University of British Columbia, Canada

Title: Novel non-genetic approach to improve the tuberculosis vaccine BCG

---

### Track 5: Recent Advances in Animal Vaccination

---

### Track 6: Adjuvants for Human / Animal Vaccines

---

### Track 9: Advancements in Vaccine Development

---

## Keynote Talk

**Kenneth Beagley**  
Deputy director, The leader of the Infectious Disease Research Program  
Institute of Health Biomedical Innovation (IHBI)  
Queensland University of Technology, Australia

Title: Chikungunya Virus vaccines?  
Andreas Suhrbier, QIMR Berghofer Medical Research Institute, Australia

---

## Session Introduction

---

## Lunch Break & Networking:

---

## Coffee Break:
Title: Enhanced Immunogenicity of A Vero Cell-derived Inactivated Japanese Encephalitis Vaccine Formulated with Advax Adjuvant
Hiroko Torinashi, Kitasato Daiichi Sankyo Vaccine Co., Ltd. Japan

Title: Lipid core peptide nanoparticles as effective delivery system to trigger humoral immune responses against Group A streptococcus (GAS)
Saranya Chandrudu, University of Queensland, Australia

Title: Optimization of nuclear-localization in a Multicomponent Non-viral Gene Delivery System
Wei Dai, University of Queensland, Australia

Title: Targeting antigenic site on RSV F protein associated with virus neutralization for vaccine design
Noushin Jaberolansar, University of Queensland, Australia

Title: Peptide-based self-assembled nanovaccine system targeting Group A Streptococcus infection
Guangzu Zhao, University of Queensland, Australia

B2B Meetings

Day 3    July 28, 2015

Keynote Forum

Istvan Toth
ARC Australian Professorial Fellow, Chair-Biological Chemistry
Professor of Pharmacy, Director of Pharmaceuticals TetraQ
Group Leader, IMB Division of Structural Biology,
The University of Queensland, Australia

Track 2: Developing Next-Gen Conjugate Vaccines
Track 17: Childhood vaccines
Track 18: Cancer vaccines
Track 20: Delivery Technologies
Track 21: Vaccines Business and Development

Session Chair: Mohammed Alsharifi, Director, Chief Scientific Officer, Gamma Vaccines, Australia

Session Introduction

Title: Vaccine Manufacturing and Clinical Trial Services for Diarrheal Disease Product Development
Rodolfo M. Alarcón, NIH, USA
Title: Anti-cancer telomerase vaccines: Are they entering the age of maturity?
Gilberto Filaci, Professor, University of Genoa, Italy

Coffee Break

Title: Impact of Myriad Decisions on Patent Eligibility of Biotechnology Inventions in Australia and USA
Simon John Potter, Principal, Spruson & Ferguson, Australia
Title: Silica nanocarriers for delivery of single dose – shelf stable nano vaccines
Neena Mitter, The University of Queensland, Australia
Title: Rotavirus vaccines: Development, implementation and impact
Julie E. Bines, University of Melbourne, Australia
Title: How promising is the development of a meningococcal semi-synthetic conjugate vaccine? - a case study
Manoj Kumar Chhikara, Hilleman Labs, India
Title: Non-targeted effects of childhood vaccines: Epidemiological evidence and emerging immunological mechanisms
Katie Flanagan, Monash University, Australia

Lunch Break

Title: Key steps in moving a vaccine from proof of concept in mice to human clinical trials
Mark Reid, Clinical Network Services (CNS) Pty Ltd, Australia
Title: Use of system biology to identify genes associated with enhanced immunogenicity to a skin patch (nanopatch) delivered vaccine
Germain J. P. Fernando, University of Queensland, Australia
Title: Immunisation using microspheres of poly glycidyl methacrylate functionalized with MSA-2 peptide to protect cattle from babesiosis
Manuel Rodriguez-Valle, QAAFI/Centre for Animal Science, Australia
Title: A Novel Quantitative Fluorescence Spectroscopy Method to Estimate the Surfactant-Induced Split Ratio of Influenza Virus
Veysel Kayser, The University of Sydney, Australia

Panel Discussion

Award Ceremony